Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Checkmate or coffee break? study tests caffeine boost for chess grandmasters

NCT ID NCT07641335

Knowledge-focused Sponsor: St. Louis University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether drinking caffeinated coffee helps professional chess players think faster and make better moves during tournament games. Twelve top-level players (rated 2300-2600 Elo) will play chess after drinking either regular coffee or decaf, without knowing which they got. Researchers will measure their accuracy, reaction time, and puzzle-solving skills to see if caffeine gives them an edge.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 12 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 50 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male and female professional chess players aged 18-50 years * Current Fédération Internationale des Échecs (FIDE) standard rating between 2300 and 2600 Elo, or achievement of a standard FIDE rating within this range during the previous 12 months * Habitual caffeine consumers consuming ≤2 cups of coffee per day * Willingness to comply with all study procedures and study visits * Ability to provide written informed consent Exclusion Criteria: * Non-caffeine users * Habitual caffeine intake exceeding 2 cups of coffee per day * Cardiovascular disorders * Metabolic disorders * Psychiatric disorders * Pregnancy or breastfeeding * Current smoking * Shift workers * Use of psychoactive medications * Participation in another clinical trial within the previous 3 months * Known allergy or intolerance to milk proteins, dairy products, or soy * Known red-green color blindness or other color vision deficiencies that may interfere with Stroop Test performance

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Attention are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

attention deficit hyperactivity disorder, inattentive type Mental Fatigue

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Attention Caffeine Cognitive performance Reaction time

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Saint Louis University

    St Louis, Missouri, 63104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.